title: Reversal of end-stage heart failure is predicted by long-term therapeutic response rather than initial hemodynamic and neurohormonal profile.
abstract: BACKGROUND
  Long waiting list periods for heart transplantation have led to clinical improvements for some patients resulting in their removal from the waiting list. This study sought to determine what characteristics differentiated those patients with a good clinical outcome from those who continued to need a transplant.
  
  
  METHODS
  The initial and final serial (every 3 months) right heart catheterization data of 60 patients awaiting transplantation were retrospectively analyzed, and the patients were divided into two groups: group A, patients who were taken off the list in follow-up because of improvement (n = 18 of 60), and group B who continued to require transplantation or died (n = 42 of 60).
  
  
  RESULTS
  For Group A, there were significant declines in right atrial pressure (9 +/- 4 to 4 +/- 3 mm Hg, initial versus final, p = 0.001), systolic pulmonary arterial pressure (51 +/- 17 to 34 +/- 6 mm Hg, p = 0.0001), with an increase in electron in ejection fraction (20% +/- 4% to 34% +/- 10%, p = 0.005). The change in cardiac output and norepinephrine level was not statistically significant. For Group B, there were no changes in the initial and final values of right atrial pressure, systolic pulmonary arterial pressure, pulmonary capillary wedge pressure, or norepinephrine levels. A significant rise in ejection fraction from 17% +/- 22% +/- 8%, p = 0.003 did occur. The majority of patients in group A (12 of 18) had idiopathic dilated cardiomyopathy. In contrast, an ischemic etiology was found in the majority of group B patients (25 of 42).
  
  
  CONCLUSIONS
  This study shows that transplant waiting list outcome cannot be predicted from a patient's initial hemodynamic or neurohormonal presentation. Rather, those patients capable of reversing their hemodynamic derangements with therapy over time are most likely to sustain a favorable clinical outcome. It appears that patients with idiopathic rather than ischemic cardiomyopathy respond more favorably to medical interventions with improved prognosis.
authors.affiliation: Department of Medicine, Henry Ford Hospital, Detroit, Mich. 48202, USA.
authors.forename: T B
authors.initials: TB
authors.lastname: Levine
authors.forename: A B
authors.initials: AB
authors.lastname: Levine
authors.forename: D
authors.initials: D
authors.lastname: Goldberg
authors.forename: B
authors.initials: B
authors.lastname: Narins
authors.forename: S
authors.initials: S
authors.lastname: Goldstein
authors.forename: M
authors.initials: M
authors.lastname: Lesch
mesh_terms: D000328:Adult; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004280:Dobutamine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004656:Enalapril / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005665:Furosemide / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D016027:Heart Transplantation / Q000502:physiology*; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood*; D015996:Survival Rate; D016896:Treatment Outcome; D014850:Waiting Lists
chemical_list: D002317:Cardiovascular Agents; D004280:Dobutamine; D004656:Enalapril; D005665:Furosemide; D007548:Isosorbide Dinitrate; D009638:Norepinephrine